Nasdaq Biotech Index To Add 11 New Stocks
The Nasdaq Biotech Index released its semi-annual re-ranking changes that will be effective November 20.
Draxis Health (DRAX) will be dropped from the index due to the new rankings.
A total of 11 new biotech stocks will be added to the index. Expect these stocks to have increased volume and to gain in price leading up to November 20. Actually, they should continue to gain after that date since many index funds that track the Nasdaq Biotech Index will have to add the stocks to their portfolios.
The new stocks to be added are:
Acorda Therapeutics, Inc. (ACOR) developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain. Acorda was recently featured by BHI after it quadrupled in price in one day.
Allos Therapeutics, Inc. (ALTH) focused on the development and commercialization of small molecule therapeutics for the treatment of cancer.
Altus Pharmaceuticals Inc. (ALTU) focused on the development and commercialization of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders.
Auxilium Pharmaceuticals Inc. (AUXL) develops and commercializes pharmaceutical products that target urologic and sexual health disorders.
Avanir Pharmaceuticals (AVNR) focused on novel treatments for chronic diseases.
Coley Pharmaceutical Group, Inc. (COLY) develops a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases and asthma and allergy.
Labopharm Inc. (DDSS) focused on the development of drugs incorporating the Company's proprietary advanced controlled-release technologies.
Emisphere Technologies, Inc. (EMIS) is developing technologies which are intended to surmount the obstacles associated with the oral administration of many currently injectable therapeutic agents.
Ligand Pharmaceuticals Incorporated (LGND) develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
Omrix Biopharmaceuticals, Inc. (OMRI) develops and markets biosurgical and passive immunotherapy products derived from human plasma.
Xenoport, Inc. (XNPT) focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs.
_
The Nasdaq Biotech Index released its semi-annual re-ranking changes that will be effective November 20.
Draxis Health (DRAX) will be dropped from the index due to the new rankings.
A total of 11 new biotech stocks will be added to the index. Expect these stocks to have increased volume and to gain in price leading up to November 20. Actually, they should continue to gain after that date since many index funds that track the Nasdaq Biotech Index will have to add the stocks to their portfolios.
The new stocks to be added are:
Acorda Therapeutics, Inc. (ACOR) developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain. Acorda was recently featured by BHI after it quadrupled in price in one day.
Allos Therapeutics, Inc. (ALTH) focused on the development and commercialization of small molecule therapeutics for the treatment of cancer.
Altus Pharmaceuticals Inc. (ALTU) focused on the development and commercialization of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders.
Auxilium Pharmaceuticals Inc. (AUXL) develops and commercializes pharmaceutical products that target urologic and sexual health disorders.
Avanir Pharmaceuticals (AVNR) focused on novel treatments for chronic diseases.
Coley Pharmaceutical Group, Inc. (COLY) develops a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases and asthma and allergy.
Labopharm Inc. (DDSS) focused on the development of drugs incorporating the Company's proprietary advanced controlled-release technologies.
Emisphere Technologies, Inc. (EMIS) is developing technologies which are intended to surmount the obstacles associated with the oral administration of many currently injectable therapeutic agents.
Ligand Pharmaceuticals Incorporated (LGND) develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
Omrix Biopharmaceuticals, Inc. (OMRI) develops and markets biosurgical and passive immunotherapy products derived from human plasma.
Xenoport, Inc. (XNPT) focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs.
_
posted by Nico at
11:56 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home